In:
The Journal of Neuroscience, Society for Neuroscience, Vol. 36, No. 2 ( 2016-01-13), p. 375-384
Abstract:
Parkinson's disease (PD) is a prevalent degenerative disorder affecting the CNS that is primarily characterized by resting tremor and movement deficits. Group I metabotropic glutamate receptor subtypes 1 and 5 (mGluR1 and mGluR5, respectively) are important targets for investigation in several CNS disorders. In the present study, we investigated the in vivo roles of mGluR1 and mGluR5 in chronic PD pathology by performing longitudinal positron emission tomography (PET) imaging in A53T transgenic ( A53T-Tg ) rats expressing an abnormal human α-synuclein (ASN) gene. A53T-Tg rats showed a dramatic decline in general motor activities with age, along with abnormal ASN aggregation and striatal neuron degeneration. In longitudinal PET imaging, striatal nondisplaceable binding potential (BP ND ) values for [ 11 C]ITDM ( N -[4-[6-(isopropylamino) pyrimidin-4-yl]-1,3-thiazol-2-yl] - N -methyl-4-[ 11 C]methylbenzamide), a selective PET ligand for mGluR1, temporarily increased before PD symptom onset and dramatically decreased afterward with age. However, striatal BP ND values for ( E )-[ 11 C]ABP688 [3-(6-methylpyridin-2-ylethynyl)-cyclohex-2-enone-( E )- O -[ 11 C]methyloxime] , a specific PET ligand for mGluR5, remained constant during experimental terms. The dynamic changes in striatal mGluR1 BP ND values also showed a high correlation in pathological decreases in general motor activities. Furthermore, declines in mGluR1 BP ND values were correlated with decreases in BP ND values for [ 18 F]FE-PE2I [( E )- N -(3-iodoprop-2 E -enyl)-2β-carbo-[ 18 F]fluoroethoxy-3β-(4-methylphenyl) nortropane] , a specific PET ligand for the dopamine transporter, a biomarker for dopaminergic neurons. In conclusion, our results have demonstrated for the first time that dynamic changes occur in mGluR1, but not mGluR5, that accompany pathological progression in a PD animal model. SIGNIFICANCE STATEMENT Synaptic signaling by glutamate, the principal excitatory neurotransmitter in the brain, is modulated by group I metabotropic glutamate receptors, including the mGluR1 and mGluR5 subtypes. In the brain, mGluR1 and mGluR5 have distinct functional roles and regional distributions. Their roles in brain pathology, however, are not well characterized. Using longitudinal PET imaging in a chronic rat model of PD, we demonstrated that expression of mGluR1, but not mGluR5, dynamically changed in the striatum accompanying pathological PD progression. These findings imply that monitoring mGluR1 in vivo may provide beneficial information to further understand central nervous system disorders.
Type of Medium:
Online Resource
ISSN:
0270-6474
,
1529-2401
DOI:
10.1523/JNEUROSCI.2289-15.2016
Language:
English
Publisher:
Society for Neuroscience
Publication Date:
2016
detail.hit.zdb_id:
1475274-8
SSG:
12
Permalink
